# Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Source: https://onco.cc/trials/nct06506955/  
OnCo record `nct06506955` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Futibatinib, Fulvestrant in metastatic cancer, run by Taiho Oncology, Inc., active and no longer recruiting.

## Summary

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. is a phase 2/3 interventional study registered as NCT06506955 by Taiho Oncology, Inc., with 15 participants planned, started 2024-10-01 and due to reach its primary completion in 2027-04. Interventions recorded: futibatinib, futibatinib, fulvestrant. Conditions listed: Advanced/Metastatic Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06506955
- Phase: 2/3
- Setting: An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study
- Sponsor: Taiho Oncology, Inc.
- Enrolled: 15

## Sources

- ClinicalTrials.gov NCT06506955: https://clinicaltrials.gov/study/NCT06506955

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [Futibatinib](https://onco.cc/drugs/futibatinib/)
- companies: [Taiho Oncology (Otsuka)](https://onco.cc/companies/taiho-oncology/)

---
JSON: https://onco.cc/api/v1/entities/nct06506955.json